ClinicalTrials.gg
RecruitingNCT07432295Updated May 14, 2026

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

A Phase 2 interventional study of Givastomig and Nivolumab in Solid Tumor, Advanced Cancer and Metastatic Cancer, sponsored by I-Mab Biopharma US Limited. Recruiting at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by I-Mab Biopharma US Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,054 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 542 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
328th of 1,863
180 · median 43
Started
2026
with 82 others
Phase 2
566 of 2,054
60 open now
Primary completion
2030-03
later than 498 of 540 live
Registered
2,005th of 2,054
by date

Among the 2,054 studies in Neoplasm Metastasis with a site in United States, this one is the 328th largest by planned enrollment of the 1,863 interventional ones that give a count, is one of 83 that started in 2026, is one of 566 in phase 2, reaches primary completion later than 498 of the 540 other live ones, and was the 2,005th registered.

Neoplasm Metastasis

4,046 studies on the registry are indexed under Neoplasm Metastasis; 889 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,054 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 690 Neoplasm Metastasis studies recruiting now, 537 (78%) set no upper age limit and 97 (14%) stop at 75 or younger; 48 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,054 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if givastomig in combination with standard therapy works to treat adults with cancer in the stomach and/or esophagus (GEA adenocarcinoma). It will also help the researchers to learn more about the safety of givastomig. The main questions it aims to answer are:

  • Does the addition of givastomig to standard therapy increase the amount of time that participants survive without progression of their cancer?
  • What toxicities do participants experience when taking givastomig?

Participants may be able to take part in the study if they have unresectable or metastatic GEA and if their cancer cells express certain proteins called Claudin 18.2 (CLDN18.2) and PD-L1. Participants whose cancer cells express a protein called HER2 cannot take part.

Up to 180 participants will be randomly assigned to received givastomig at one of two doses in combination with an immunotherapy medicine called nivolumab and chemotherapy OR to receive nivolumab and chemotherapy alone. These therapies will be given primarily via intravenous (into a vein) infusion every 2 or 3 weeks.

Participants will:

  • Visit the study treatment center for infusions and/or check-ups and tests every 1-3 weeks
  • Report any changes in their symptoms to their study doctors
  • Have scans to check for any changes in their cancer every 8-12 weeks
Read the detailed description

This is a randomized, global, open-label, multicenter Phase 2 study evaluating the efficacy and safety of givastomig (TJ033721) in combination with nivolumab and chemotherapy compared with nivolumab and chemotherapy alone in participants with previously untreated, HER2-negative, CLDN18.2-positive, and PD-L1-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (GEA).

Approximately 180 participants will be randomized in a 1:1:1 ratio to one of three treatment arms. Two investigational arms will receive givastomig in combination with nivolumab and chemotherapy, and the control arm will receive nivolumab and chemotherapy alone. Chemotherapy will consist of either modified FOLFOX (mFOLFOX) or CAPOX, administered according to local standard of care. Participants enrolled in the United States, Japan, and South Korea will receive mFOLFOX only. Randomization will be stratified by chemotherapy regimen (mFOLFOX vs CAPOX) and by CLDN18.2 expression level (\<75% vs ≥75% of tumor cells with membrane intensity score ≥2+).

Participants in the investigational arms will receive givastomig administered every 2 weeks or every 3 weeks, depending on the chemotherapy regimen. Tumor assessments will be performed at protocol-defined intervals and evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Enrollment of participants with high CLDN18.2 expression (defined as membrane intensity score ≥1+ in ≥75% of tumor cells) will be capped at approximately 50% of the total study population. Enrollment of participants receiving CAPOX will be capped at approximately 30% of the total study population.

Study treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, death, or completion of study treatment, whichever occurs first. The duration of chemotherapy treatment will follow the respective product labeling or local standards of care.

03

Conditions studied

  • Solid Tumor
  • Advanced Cancer
  • Metastatic Cancer
  • Gastric Cancer
  • Gastroesophageal Junction Carcinoma
  • Esophageal Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed unresectable, locally advanced, or gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma (EAC).
  • Treatment-naïve for advanced/metastatic disease (prior /neoadjuvant therapy allowed if ≥6 months since last dose).
  • CLDN18.2 positive (membrane intensity score ≥1+ on ≥1% of tumor cells).
  • positive (CPS ≥1).
  • At least 1 per v1.1.
  • performance status 0 or 1.
  • Adequate organ function, including:

    • Hematologic: WBC ≥2,000/μL; ≥1,500/μL; ≥100,000/μL; ≥9 g/dL
    • Hepatic: /ALT ≤3× (≤5×ULN if liver metastases); ≤1.5×ULN (≤3×ULN if Gilbert's)
    • Renal: Creatinine ≤1.5×ULN or ≥50 mL/min/1.73 m²
  • ≥90 days.
  • Women of (WOCBP) and men must use effective during the study and for a defined period after treatment.
  • Willing and able to provide and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • -positive tumors.
  • Second within 3 years, except certain skin or cervical cancers.
  • Active or unstable gastrointestinal ulcer or bleeding within 6 weeks.
  • Active disease requiring systemic therapy within past 2 years or ongoing therapy.
  • Active pneumonitis or history requiring /immunosuppressive therapy within 3 years.
  • Participation in another therapeutic clinical trial.
  • Major surgery or significant injury within 4 weeks prior to first dose, or planned major surgery within 6 months.
  • Radiotherapy within protocol-specified timeframes without adequate recovery.
  • Active or carcinomatous meningitis (previously treated brain metastases allowed if stable).
  • Significant cardiovascular disease ( Class 3-4 CHF, recent MI, unstable angina, /stroke, or major cardiac procedures within 6 months).
  • Active or uncontrolled , , or infection, or immunodeficiency (controlled infection allowed).
  • Receipt of within 30 days or other vaccines within 7 days of first dose.
  • Active infection requiring parenteral therapy.
  • Known to study drug components (e.g., DPD deficiency).
  • Any other condition or laboratory abnormality that, in the investigator's judgment, increases risk or interferes with study participation.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Experimental: Givastomig Arm 1 Combination

    Givastomig (IV) 8 mg/kg every 2 weeks (Q2W) in combination with nivolumab and modified FOLFOX (mFOLFOX) or Givastomig 12 mg/kg every 3 weeks (Q3W) in combination with nivolumab and CAPOX

    Drug: Givastomig · Drug: Nivolumab · Drug: 5Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Experimental: Givastomig Arm 2 Combination

    Givastomig (IV) 12 mg/kg every 2 weeks (Q2W) in combination with nivolumab and modified FOLFOX (mFOLFOX) or Givastomig 18 mg/kg every 3 weeks (Q3W) in combination with nivolumab and CAPOX

    Drug: Givastomig · Drug: Nivolumab · Drug: 5Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin · Drug: Capecitabine

  • Active comparator
    Control: Nivolumab Plus Chemotherapy

    Nivolumab in combination with modified FOLFOX (mFOLFOX) or CAPOX

    Drug: Nivolumab · Drug: 5Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS), BICR-assessed

    Compare PFS between participants receiving givastomig plus nivolumab and chemotherapy versus control (nivolumab plus chemotherapy)

    Time frame: Up to 5 years

  2. Safety and Tolerability

    Incidence, severity, and type of adverse events, including treatment-emergent and immune-related adverse events, graded by NCI CTCAE v5.0

    Time frame: Throughout treatment and up to 30 days after last dose

Secondary outcomes

  1. Objective Response Rate (ORR), BICR-assessed

    Proportion of participants with complete or partial response by RECIST v1.1

    Time frame: Up to 108 weeks

  2. Duration of Response (DOR), BICR-assessed

    Time participants maintain complete or partial response

    Time frame: Up to 108 weeks

  3. Best Overall Response (BOR), BICR-assessed

    Best response achieved during treatment according to RECIST v1.1

    Time frame: Up to 108 weeks

  4. Overall Survival (OS)

    Comparison of overall survival between arms

    Time frame: Up to 5 years

  5. Optimized Dose of Givastomig

    Determine the recommended dose of givastomig in combination with nivolumab and chemotherapy

    Time frame: Up to 2 years

  6. Peak Plasma Concentration (Cmax) of Givastomig

    Cmax will be derived from the PK plasma samples collected

    Time frame: Up to 2 years

  7. Correlation of baseline CLDN18.2 expression with response and safety measures

    Tumor expression of CLDN18.2 will be assessed at baseline and will be correlated with measures of response (including ORR, PFS, OS) and safety (incidence of AEs)

    Time frame: Baseline and up to 2 years

  8. Change in serum levels of soluble 4-1BB (s4-1BB) from baseline

    Serum s4-1BB levels will be assessed at baseline and while on treatment. Changes will be correlated with efficacy measures including ORR.

    Time frame: Baseline and up to 2 years

  9. Health Related Quality of Life (HRQoL) measured by the Quality of Life Questionnaire - Core Questionnaire (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a cancer specific instrument consisting of 5 functional domain scales: physical, role, emotional, social, and cognitive

    Time frame: Baseline and up to 2 years

  10. Trough Plasma Concentration (Ctrough) of Givastomig

    Ctrough will be derived from the PK plasma samples collected

    Time frame: Up to 2 years

  11. Number of participants positive for anti-drug antibody (ADA) to Givastomig

    Immunogenicity will be measured by the number of participants that are ADA positive

    Time frame: Up to 2 years

  12. Correlation of baseline PDL1 expression with response and safety measures

    Tumor expression of PDL1 will be assessed at baseline and will be correlated with measures of response (including ORR, PFS, OS) and safety (incidence of AEs)

    Time frame: Baseline and up to 2 years

  13. HRQoL measured by the Oesophago-Gastric Module (EORTC QLQ-OG25) questionnaire

    The EORTC-QLQ-OG25 questionnaire evaluates gastric cancer and gastroesophageal cancer specific symptoms

    Time frame: Baseline and up to 2 years

  14. HRQoL measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L)

    he EQ-5D-5L questionnaire is a validated measure of generic health outcomes including mobility, self-care, usual activities, pain/depression, and anxiety/depression

    Time frame: Baseline and up to 2 years

07

Study locations

5 of 6 sites recruiting
  • I-Mab Site 1016
    Goodyear, Arizona 85338, United States
    Recruiting
    • I-Mab PI - 1016 · Contact
  • I-MAB Site 1005
    Duarte, California 91010, United States
    Recruiting
    • I-MAB PI - 1005 · Contact
  • I-Mab Site 1002
    Boston, Massachusetts 02114, United States
    Recruiting
    • I-Mab PI - 1002 · Contact
  • I-Mab Site 2001
    Beijing, China
    Recruiting
    • I-Mab PI - 2001 · Contact
  • I-Mab Site - 4001
    Kashiwa, Japan
    Not yet recruiting
    • I-Mab PI 4001 · Contact
  • I-Mab Site 4005
    Tokyo, Japan
    Recruiting
    • I-Mab PI - 4005 · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Mar 2030, 49 months after the start.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's planned 49 months is above that.

Counting every sponsor, half of 443 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Feb 25, 2026
StartActual
Feb 11, 2026
Primary completionEst.
Mar 2030
CompletionEst.
Aug 2030
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07432295
Lead sponsor
I-Mab Biopharma US Limited
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Feb 11, 2026
Primary completion
Mar 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
May 14, 2026

Study contacts

I-MAB US Clinical Trials
Contact
us.info@imabbio.com
301-294-4408

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion